Patterson Companies Inc PDCO reports Q3 FY22 sales of $1.59 billion, +2.9% Y/Y, missing the consensus of $1.63 billion.
- Dental segment sales reached $650.6 million. Internal sales increased 0.1% Y/Y, including a 1.8% decline in consumables due to the expected moderation of infection control products compared to the pandemic-related performance last year and the impact from the omicron variant.
- Animal Health segment sales reached $944.8 million. Internal sales growth of 8.2% was driven by continued strong performance in companion animals and additional recovery in production animals.
- The gross margin improved from 20.9% to 21.1%.
- Patterson reported an adjusted EPS of $0.55, surpassing the consensus of $0.50, and lower than $0.58 posted a year ago.
- Guidance: Patterson Companies updated its FY22 adjusted EPS guidance to $2.08 - $2.13, compared to prior guidance of $2.00 - $2.10 and the consensus of $2.07.
- Price Action: PDCO shares traded higher by 4.21% at $30.66 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in